Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

N. Sommer, R. Martin, H. F. McFarland, L. Quigley, B. Cannella, C. S. Raine, D. E. Scott, P. A. Löschmann, M. K. Racke

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

It was recently demonstrated that selective phosphodiesterase type 4 (PDE4) inhibition suppresses the clinical manifestations of acute experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and inhibits the production of tumor necrosis factor-α (TNF- α), a pathogenetically central cytokine. Since the most common presentation of MS in humans is a relapsing-remitting course, we investigated the therapeutic potential of PDE4 inhibition in the relapsing-remitting EAE model of the SJL mouse. Administration of rolipram, the prototypic PDE4 inhibitor, reduced the clinical signs of EAE during both the initial episode of disease and subsequent relapses. In parallel, there was marked reduction of demyelination and also less inflammation throughout the central nervous system (CNS) of rolipram-treated animals. Gene expression of proinflammatory cytokines in the CNS was reduced in most of the rolipram-treated animals. Additional experiments demonstrated that PDE4 inhibition acted principally by inhibiting the secretion of Th1 cytokines, however, the encephalitogenic potential of myelin basic protein-specific T cells was not impaired. Our findings suggest that PDE4 inhibitors are a promising cytokine-directed therapy in chronic demyelinating disease.

Original languageEnglish (US)
Pages (from-to)54-61
Number of pages8
JournalJournal of Neuroimmunology
Volume79
Issue number1
DOIs
StatePublished - Oct 1997

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Demyelinating Diseases
Rolipram
Autoimmune Diseases
Autoimmune Experimental Encephalomyelitis
Phosphodiesterase 4 Inhibitors
Cytokines
Multiple Sclerosis
Central Nervous System
Myelin Basic Protein
Therapeutics
Chronic Disease
Animal Models
Tumor Necrosis Factor-alpha
Inflammation
T-Lymphocytes
Gene Expression
Recurrence

Keywords

  • Cytokine
  • Experimental autoimmune encephalomyelitis
  • Multiple sclerosis
  • Phosphodiesterase type 4
  • Rolipram
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Sommer, N., Martin, R., McFarland, H. F., Quigley, L., Cannella, B., Raine, C. S., ... Racke, M. K. (1997). Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. Journal of Neuroimmunology, 79(1), 54-61. https://doi.org/10.1016/S0165-5728(97)00111-2

Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. / Sommer, N.; Martin, R.; McFarland, H. F.; Quigley, L.; Cannella, B.; Raine, C. S.; Scott, D. E.; Löschmann, P. A.; Racke, M. K.

In: Journal of Neuroimmunology, Vol. 79, No. 1, 10.1997, p. 54-61.

Research output: Contribution to journalArticle

Sommer, N, Martin, R, McFarland, HF, Quigley, L, Cannella, B, Raine, CS, Scott, DE, Löschmann, PA & Racke, MK 1997, 'Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease', Journal of Neuroimmunology, vol. 79, no. 1, pp. 54-61. https://doi.org/10.1016/S0165-5728(97)00111-2
Sommer, N. ; Martin, R. ; McFarland, H. F. ; Quigley, L. ; Cannella, B. ; Raine, C. S. ; Scott, D. E. ; Löschmann, P. A. ; Racke, M. K. / Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. In: Journal of Neuroimmunology. 1997 ; Vol. 79, No. 1. pp. 54-61.
@article{ab27a3c53fbf4a3e93c384ffba4ef568,
title = "Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease",
abstract = "It was recently demonstrated that selective phosphodiesterase type 4 (PDE4) inhibition suppresses the clinical manifestations of acute experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and inhibits the production of tumor necrosis factor-α (TNF- α), a pathogenetically central cytokine. Since the most common presentation of MS in humans is a relapsing-remitting course, we investigated the therapeutic potential of PDE4 inhibition in the relapsing-remitting EAE model of the SJL mouse. Administration of rolipram, the prototypic PDE4 inhibitor, reduced the clinical signs of EAE during both the initial episode of disease and subsequent relapses. In parallel, there was marked reduction of demyelination and also less inflammation throughout the central nervous system (CNS) of rolipram-treated animals. Gene expression of proinflammatory cytokines in the CNS was reduced in most of the rolipram-treated animals. Additional experiments demonstrated that PDE4 inhibition acted principally by inhibiting the secretion of Th1 cytokines, however, the encephalitogenic potential of myelin basic protein-specific T cells was not impaired. Our findings suggest that PDE4 inhibitors are a promising cytokine-directed therapy in chronic demyelinating disease.",
keywords = "Cytokine, Experimental autoimmune encephalomyelitis, Multiple sclerosis, Phosphodiesterase type 4, Rolipram, Tumor necrosis factor",
author = "N. Sommer and R. Martin and McFarland, {H. F.} and L. Quigley and B. Cannella and Raine, {C. S.} and Scott, {D. E.} and L{\"o}schmann, {P. A.} and Racke, {M. K.}",
year = "1997",
month = "10",
doi = "10.1016/S0165-5728(97)00111-2",
language = "English (US)",
volume = "79",
pages = "54--61",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

AU - Sommer, N.

AU - Martin, R.

AU - McFarland, H. F.

AU - Quigley, L.

AU - Cannella, B.

AU - Raine, C. S.

AU - Scott, D. E.

AU - Löschmann, P. A.

AU - Racke, M. K.

PY - 1997/10

Y1 - 1997/10

N2 - It was recently demonstrated that selective phosphodiesterase type 4 (PDE4) inhibition suppresses the clinical manifestations of acute experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and inhibits the production of tumor necrosis factor-α (TNF- α), a pathogenetically central cytokine. Since the most common presentation of MS in humans is a relapsing-remitting course, we investigated the therapeutic potential of PDE4 inhibition in the relapsing-remitting EAE model of the SJL mouse. Administration of rolipram, the prototypic PDE4 inhibitor, reduced the clinical signs of EAE during both the initial episode of disease and subsequent relapses. In parallel, there was marked reduction of demyelination and also less inflammation throughout the central nervous system (CNS) of rolipram-treated animals. Gene expression of proinflammatory cytokines in the CNS was reduced in most of the rolipram-treated animals. Additional experiments demonstrated that PDE4 inhibition acted principally by inhibiting the secretion of Th1 cytokines, however, the encephalitogenic potential of myelin basic protein-specific T cells was not impaired. Our findings suggest that PDE4 inhibitors are a promising cytokine-directed therapy in chronic demyelinating disease.

AB - It was recently demonstrated that selective phosphodiesterase type 4 (PDE4) inhibition suppresses the clinical manifestations of acute experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and inhibits the production of tumor necrosis factor-α (TNF- α), a pathogenetically central cytokine. Since the most common presentation of MS in humans is a relapsing-remitting course, we investigated the therapeutic potential of PDE4 inhibition in the relapsing-remitting EAE model of the SJL mouse. Administration of rolipram, the prototypic PDE4 inhibitor, reduced the clinical signs of EAE during both the initial episode of disease and subsequent relapses. In parallel, there was marked reduction of demyelination and also less inflammation throughout the central nervous system (CNS) of rolipram-treated animals. Gene expression of proinflammatory cytokines in the CNS was reduced in most of the rolipram-treated animals. Additional experiments demonstrated that PDE4 inhibition acted principally by inhibiting the secretion of Th1 cytokines, however, the encephalitogenic potential of myelin basic protein-specific T cells was not impaired. Our findings suggest that PDE4 inhibitors are a promising cytokine-directed therapy in chronic demyelinating disease.

KW - Cytokine

KW - Experimental autoimmune encephalomyelitis

KW - Multiple sclerosis

KW - Phosphodiesterase type 4

KW - Rolipram

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0030660328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030660328&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(97)00111-2

DO - 10.1016/S0165-5728(97)00111-2

M3 - Article

C2 - 9357447

AN - SCOPUS:0030660328

VL - 79

SP - 54

EP - 61

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1

ER -